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A treatment strategy of advanced melanoma is dramatically changing, due to immune-
checkpoint inhibitors and BRAF/ MEK inhibitors. Nevertheless, reliable serum markers 
for evaluation of treatment responses and the outcome are still limited. Some previous 
reports suggested serum neuron specific enolase (sNSE) might be a useful marker for 
melanoma, however the usefulness is controversial. Moreover, NSE has not been 
examined in in-vitro by using melanoma cell lines. We retrospectively evaluated sNSE 
and Serum lactate dehydrogenase (sLDH) levels at the initial diagnosis and during 
therapy in 33 melanoma patients at various stages. We analysed the NSE concentrations 
in cell lysates and supernatants from melanoma cell lines by enzyme-linked 
immunosorbent assay. The median sNSE was significantly higher in stage IV patients 
compared to stages I/II and III (16.3, 12.7, and 12.1 ng/ml, respectively). sNSE was 
elevated in 20% (2/10) of stage III and 61.1% (11/18) of stage IV patients but not in stage 
I/II. sNSE and sLDH tended to correspond to the total tumor volume (p=0.48 and 0.58, 
95%CI: 0.005–0172 and 0.776–0.836, respectively). The coincidence rate of sNSE and 
sLDH in stage IV at the initial diagnosis was 11/18 (61.1%). Of the remaining patients, 
elevated sNSE but not sLDH was observed in five patients (27.8%) and elevated sLDH 
but not sNSE was observed in two (11.1%). Four of the five patients showing elevated 
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sNSE and normal sLDH were the mucosal type. NSE was detected in both supernatant 
and cell lysate of all four melanoma cell lines (0.30–237.32 ng/ml and 137–483.04 ng/mg, 
respectively). Two cell lines with a high supernatant NSE level contained many dead cells 
in the supernatant. The combination of sNSE and sLDH could contribute to the early 
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In recent years, the advance of new therapeutic agents including immune-checkpoint 
inhibitors and BRAF/MEK inhibitors has dramatically changed the treatment for 
advanced malignant melanoma. Although the clinical response of patients with this 
melanoma is usually evaluated by imaging examinations, there is a risk of delay in 
detecting disease progression. Easily obtained real-time markers including serological 
biomarkers are thus required for the detection of tumor growth and metastases and the 
monitoring of therapeutic outcomes. 
The serum level of lactate dehydrogenase (sLDH) has been one of the most useful 
biomarkers1 and is essential for the stage grouping described by the American Joint 
Committee on Cancer/International Union for Cancer Control (AJCC/UICC).2,3 An 
elevated sLDH level is associated with poor prognosis and a low response to systemic 
therapy in stage IV patients . 4 sLDH has also been reported to be a useful serum marker 
as a prognostic factor in other solid tumors. 5 However, sLDH is not specific for melanoma 
and can be elevated due to various factors such as hemolysis, infection, and hepatocellular 
injuries. 
Neurone-specific enolase (NSE) is a 78-kD gamma-homodimer that acts as a 
dominant enolase-isoenzyme in neuronal and neuroendocrine tissues. NSE is also known 
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as enolase 2 and is encoded by the ENO2 gene in humans. NSE is commonly used as a 
serum marker of small cell lung cancer, neuroendocrine tumors, and Merkel cell 
carcinoma. Reports from the 1980s and 1990s suggested that (1) serum NSE (sNSE) 
could be correlated with the disease stage and (2) the sNSE level corresponds to sLDH in 
advanced melanoma. 6-9 However, other reports showed no correlation between sNSE and 
disease progression. 10,11 
Because of the recent advances in treatment by immune-checkpoint inhibitors and 
small molecular targeted agents, we examined the usefulness of sNSE as a serum 
biomarker in melanoma, and we studied the concentrations of sNSE in both the 
supernatant and cell lysate of several melanoma cell lines because there are no published 
in vitro data regarding NSE. 
 
MATERIALS AND METHODS 
Patients 
We retrospectively analyzed the clinical of 33 melanoma patients treated at Sapporo 
Medical University Hospital from 2014 to 2016. The staging was performed according to 
the criteria of the AJCC 2017 based on the tumor, node, metastasis (TNM) system. 
Clinical staging in the vaginal malignant melanoma was performed according to the 
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International Federation of Gynecology and Obstetrics (FIGO) classification. 
 
The measurement of serum NSE and serum LDH levels 
Each patient's sNSE and sLDH levels were measured at the initial visit to our hospital 
and at the routine blood examinations during the follow-up. The sNSE and sLDH levels 
were determined using conventional methods at the Department of Laboratory Medicine, 
Sapporo Medical University Hospital. The sNSE levels were measured by an 
electrochemiluminescence immunoassay (ECLIA), and the sLDH levels were measured 
by ultraviolet absorption spectrophotometry. The reference ranges were as follows. sNSE: 
0.0–15.2 ng/ml, sLDH: 124–222 IU/L. 
 
NSE immunohistochemistry (IHC) 
We performed an immunohistochemistry (IHC) analysis using slides of formalin-fixed 
paraffin-embedded (FFPE) tumor samples and automated staining techniques (BOND-
MAX, Leica Microsystem, Tokyo). The primary antibody against NSE was the N1557 
mouse monoclonal antibody (dilution: ready-to-use) (Dako, Santa Clara, CA). The NSE 
expression was evaluated by IHC in the 15 stage IV patients. 8 patients were examined 
both primary lesion and metastatic specimens and 3 patients were examined primary 
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lesion specimens and 4 patients were examined metastatic specimens. The Giemsa 
staining was performed to distinguish between diaminobenzidine (DAB) staining and 
melanin. 12  
 
The measurement of the total tumor volume 
We evaluated the disease activity by determining the total tumor volume with the use of 
computed tomography (CT) or magnetic resonance imaging (MRI). The total tumor 
volume was calculated by multiplying the sum of the tumor areas and the slice thickness. 
We evaluated the correlation between disease activity and the serum NSE levels in nine 
patients of stage IV. We also investigated the relationship between total tumor volume 
and the sNSE or sLDH levels when new metastasis was detected by an imaging study. 
Patients with unmeasurable metastases such as peritoneum dissemination and bone 
metastases were excluded from this analysis. 
 
The melanoma cell lines 
The four cultured melanoma cell lines used in this study were M-418, SK-mel-118, SK-
mel-23, and MeWo. M-418 is a pigmented human melanoma cell line that was kindly 
supplied by P.G. Parsons, Queensland Institute of Medical Research, Brisbane, Australia. 
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SK-mel-23 is a pigmented human melanoma cell line taken from a 67-year-old woman 
with cutaneous melanoma (no description of race). MeWo is a pigmented human 
melanoma cell line taken from a 78-year-old Caucasian man with cutaneous melanoma. 
SK-mel-118 is a non-pigmented human melanoma cell. The determination of these 
melanoma cell lines as pigmented or non-pigmented was based on the cell lines' melanin 
production ability observed in our laboratory. 13 
All four of these human melanoma cell lines were cultured in Gibco Dulbecco's 
Modified Eagle Medium® (DME) supplemented with 8% fetal bovine serum (FBS, 
Sigma-Aldrich, St. Louis, MO), into which was added penicillin G sodium salt (1%) and 
streptomycin sulfate (1%). The cells were cultured in a humidified 5% CO2 incubator at 
37°C. The human fibroblast cell line Tig 118 and the human glioblastoma cell line T98G 
were cultured by the same method. The growth rate of each cell line was also measured 
by counting the number of live cells in each 10-cm dish. 
 
NSE in the supernatant sample preparation and collection 
Using a protocol originally developed for glioblastoma cells which were used in a uveal 
melanoma secretome analysis, 14 we incubated melanoma cells with 10 mL of serum-free 
medium (SFM) for 1 hr and rinsed once again with fresh SFM. The cells were then 
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incubated with 8 mL of SFM for 48 hr, and the conditioned medium at the end of the 
incubation period was collected. For each sample, the number of dead cells was counted 
in the medium, and the secreted protein from each 10-cm dish was pooled into a 30-ml 
universal tube and centrifuged at 300 g for 5 min at 4°C to pellet any floating cells. 
 
Cell count 
A cell counter (Countess® II FL, Thermo Fisher Scientific, Waltham, MA) was used to 
count the number of cells in the supernatants and the culture dishes. The numbers of cells 
were counted by using 10 μl of 4% trypan blue mixed with 10 μl of the sample. Cells that 
were stained blue with 4% trypan blue were counted as dead cells by the cell counter. 
 
Enzyme-linked immunosorbent assay (ELISA) 
The NSE in the cell lysates and cell culture supernatants was analyzed by an enzyme-
linked immunosorbent assay (ELISA). We used a commercially available kit (Human 
Enolase 2 DENL20 ELISA, R&D Systems, Minneapolis, MN), and the assay was 
performed according to the manufacturer's recommendations. The analysis of cell lysates 
was performed using cell cultures of Tig118, M-418, SK-mel-23, MeWo, SK-mel-118, 
and T98G cells. The analysis of secreted proteins was performed using cell cultures of 
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M-418, SK-mel-23, MeWo, SK-mel-118, and Tig118 cells. 
 
Statistical analyses 
All statistical analyses were performed using the Bell Curve for Excel ver. 2.02 (Social 
Survey Research Information, Tokyo). We used the Mann-Whitney U-test to compare the 
median sNSE levels among groups of patients with different stages of melanoma. The 
significance level was set at p<0.05. We used Pearson’s product-moment correlation 
coefficient test to analysis the correlation between tumor volume and sNSE or sLDH and 
Spearman’s rank correlation test to evaluate the correlation between sNSE and sLDH. 
 
Ethics 
This study was approved by the Institutional Review Board of the Sapporo Medical 




The stages of the 33 melanoma patients were as follows: stage I or II, n=5; stage III, n=10; 
stage IV, n=18. The patients' median ages were stage I/II (64 yrs), stage III (67.5 yrs) and 
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stage IV (80 yrs). The male/female distribution at each stage was I/II (2/3), stage III (4/6), 
and stage IV (7/11). The primary site at each stage was I/II (one cutaneous and four acral 
malignant melanoma [ALM]), III (one cutaneous, nine ALM), and IV (three cutaneous, 
seven ALM, and eight mucosal type). The primary sites of the eight mucosal-type 
melanomas were nasal (n=4), oral (n=1) and vaginal (n=3) (Table 1). 
 
Serum NSE levels and the stages 
The sNSE levels of the patients at their initial diagnoses at each stage are shown in 
Fig. 1. Two patients with stage IV disease who had extensive metastatic disease at the 
time of their initial diagnoses were excluded because both their sNSE and sLDH levels 
were abnormally high (Fig. 1). The sNSE levels were over the normal range in 13 (stage 
III: n=2, IV: n=11) of the 33 patients. The rates of the patients with elevated sNSE at each 
stage were 0% (0/5) in the stage I/II group, 20% (2/10) for stage III, and 61.1% (11/18) 
for stage IV (Fig. 1, Table 2). The median sNSE levels at each stage were 12.7, 12.1, and 
16.3 ng/ml for stages I/II, III and IV, respectively. The sNSE levels of the stage IV patients 
were significantly higher than those of the stage I/II and III patients. The sNSE levels of 
the two stage III patients who had elevated sNSE levels were 15.5 and 16.5 ng/ml. The 
levels of sNSE didn’t correlate with age, sex, Breslow thickness, ulcer, mitosis or sentinel 
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lymph node involvement. 
 
The relationships between the serum NSE and LDH levels in the stage IV group 
Thirteen (72.2%) of the 18 stage IV patients showed elevated sNSE, elevated LDH, or 
both. Among the 18 stage IV patients, the sLDH level was elevated in eight (44.4%) 
compared to 61.1% with sNSE (Table 2). Of these, both elevated sNSE and elevated 
sLDH were observed in six (33.3%) patients, only elevated sNSE (not sLDH) was 
observed in five (27.8%) patients, and only elevated sLDH (not sNSE) was observed in 
two (11.1%) patients. Four of the five patients showing elevated sNSE and normal sLDH 
had the mucosal type of melanoma (case 3, 8, 13 and 16). No clinical characteristics was 
detected in the two patients who showed normal sNSE and elavated sLDH results. Both 
sLDH and sNSE level were not elevated in five (27.8%) patients (Table 2). The 
coincidence rate of sNSE and sLDH including the patients showing both elevated and 
both normal was 61.1% (both elevated, n=6 patients; both normal, n=5). There was no 
correlation between sNSE and sLDH (rs=0.2, p=0.46). 
 
The IHC results and serum NSE 
Immunohistochemically, the tumor samples from 14 of the 15 stage IV patients showed 
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positive for NSE (Table 1). NSE IHC was not expressed in 1 of 15 examined cases 
(Fig2A). The two positive staining pattern, focal (2B) and diffuse (2C) was observed. 
sNSE level of this negative case was within the normal range. However, the results of 
NSE IHC were not associated with those of sNSE level, because sNSE level was within 
the normal range in 6 cases showing positive for NSE IHC. 
 
The total tumor volumes and serum NSE and LDH levels 
Fig. 3 illustrates the relationships between the total tumor volume and the sNSE levels 
and sLDH levels of 15 of the stage IV patients. The correlation coefficients between the 
total tumor volume and sNSE and sLDH were 0.48 [95%CI: 0.005–0.172] and 0.59 
[95%CI: 0.776–0.836], respectively and both showed a significant positive correlation. 
The patients with a large total tumor volume tended to show elevated sNSE and sLDH 
levels and we determined the moderate correlations of the sNSE or sLDH level with the 
tumor volume. 
 
Serum NSE and LDH levels and the change of tumor volumes in the stage IV 
patients 
Nine patients with stage IV melanoma were available for our evaluation of the changes 
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in the total tumor volume (primary and metastasis lesions) (Fig. 4). The movement of the 
patients' sNSE and sLDH values basically corresponded to the total tumor volume (Fig. 
4). However, in two cases (patients 4, 10), the sNSE and sLDH changes were not 
consistent with the tumor volume changes. In the patient 4, the sLDH level kept within 
the normal range although sNSE was increase corresponding to an increase in tumor 
volume. In the patient 10 showing a marked decrease in the tumor volume, both sLDH 
and sNSE levels showed a small variation although the sNSE level was consequently 
normalized. 
 
The NSE levels of the cell lysates and supernatants 
NSE was detected in the cell lysates of all of the examined cell lines, i.e., the four 
melanoma cell lines (M-418, MeWo, SK-mel-23 and SK-mel-118), the human 
glioblastoma cell line (T98G), and the human fibroblast cell line (Tig118). The median 
NSE value in the cell lysates was 175.19 ng/mg (range: 137.26–483.04 ng/mg) (Fig. 5A). 
Among the cell supernatants, NSE was detected in only the four melanoma cell lines 
(0.30–237.31 ng/ml) (Fig. 5B), and not in the human fibroblast line (Fig. 5B). 
The difference between pigmented melanoma cell lines and non-pigmented 
melanoma cell lines didn’t affect NSE in cell lysate and supernatant. Large amounts of 
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NSE were detected in both cell lysates and supernatants of the cell lines SK-mel-23 and 
AK-mel-118, whereas NSE was detected in the cell lysates of M-418 and MeWo but only 
slightly in these cell lines' supernatants. The evaluation of the number of dead cells in the 
supernatants showed that the supernatants of the SK-mel-23 cells and SK-mel-118 cells 
contained numerous dead cells whereas the supernatants of the M-418 and MeWo cells 
contained none or scant dead cells (Fig. 5C). 
 
DISCUSSION 
Enolase is a dimeric glycolytic enzyme composed of two of the three subunits α, β, and 
γ. There are five known combinations of enolase other than the βγ form. The αγ and γγ 
types with a γ subunit are called neurone-specific enolase (NSE). NSE is a highly specific 
marker for neurones and peripheral neuroendocrine tissue, but immunostaining 
techniques have also demonstrated that NSE is present in a variety of normal cells 
including pinealocytes, pituitary glandular and peptide-secreting cells, thyroid 
parafollicular cells, adrenal medullary chromaffin cells, cells of the islets of Langerhans, 
Merkel's cells of the skin, neuroendocrine cells of the lung, and erythrocytes. 15 The sNSE 
is thought to be released from damaged or broken tumor cells. NSE that is produced when 
inflammation occurs in neuronal cells causes the breakdown of the extracellular matrix, 
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the production of inflammatory cytokines and chemokines, and the infiltration of 
inflammatory cells other than enolase-isoenzyme. 16 
NSE has been demonstrated to provide quantitative measures of brain damage and 
to contribute to more precise diagnosis and outcome evaluations of patients with ischemic 
stroke, intracerebral hemorrhage, or seizures, and comatose patients after 
cardiopulmonary resuscitation for cardiac arrest or traumatic brain injury. 17 Increased 
NSE serum levels have also been shown to be associated with melanoma, seminoma, 
renal cell carcinoma, Merkel cell tumor, carcinoid tumors, dysgerminomas, immature 
teratomas, malignant phaeochromocytoma, Guillain-Barre syndrome, and Creutzfeldt-
Jakob disease. 17 
Our present analyses revealed that the sNSE level was elevated in 20% of the 10 
stage III patients and 61.1% of the 18 stage IV patients but none of the five stage I/II 
patients. The elevation of sNSE was mild in two of the stage III patients. A correlation 
between sNSE levels and disease stage or tumor burden has been described, 6,7 but there 
are some conflicting reports. 10,11 Our data suggest that the sNSE level is elevated under 
the condition of disease progression of melanoma, particularly at stage IV. 
The positive rate of elevated sNSE in our study was 61%, which is higher than the 
reported rates (34%–48%). 7 This difference may be due to the use of different methods 
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and patient profiles among the studies. We used an ECLIA which was highly sensitive, 
whereas the previous studies used the immunoradiometric assay that was commonly used 
in the 1980s–90s. 
To date, sLDH has been one of the most useful biomarkers for the management of 
melanoma patients. Its level is used as a prognostic factor for stage-grouping in the AJCC 
system. 18 Moreover, sLDH is known to be related to the clinical response to immune 
checkpoint inhibitors and BRAF/MEK inhibitors. We, therefore, compared the usefulness 
of sNSE to that of sLDH, and our analyses revealed that the coincidence rate of sNSE and 
sLDH in patients with stage IV melanoma was 61.1% (11 of the 18 patients: six both 
positive and five both negative). Of the remaining seven patients showing different 
patterns between sNSE and sLDH, elevated sNSE but not sLDH was observed in five 
patients (27.8%), and elevated sLDH but not sNSE was observed in the other two (11.1%). 
Despite the small number of patients, these results suggested that some patients with 
advanced melanoma may be more likely to have elevated sNSE than sLDH as the disease 
progression. 
Four of the present five stage IV patients showing elevated sNSE but not sLDH 
had mucosal-type melanomas. The mucosal type was reported in 10% of Japanese 
melanoma patients, 19 but clinical trials and real-world data in Japan have shown that the 
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mucosal type accounts for 25%–40% of the melanoma patients who required systemic 
therapy in the advanced stage. 20,21 Because of the limited number of the cases, it is 
necessary to examine greater numbers of melanoma patients to determine the precise 
usefulness of NSE as a biomarker of mucosal melanoma and its potential superiority to 
LDH. 
We examined the relationship between the change of the total tumor volume and 
sNSE because previous studies investigated only the association of sNSE levels, disease 
stage, and the number of metastasis sites. 7,10 We also compared the changes in sNSE to 
the changes in sLDH in a group of 15 stage IV patients; the correlation coefficient 
between the total tumor volume and sNSE was 0.48 (95%CI: 0.005–0.172) and that 
between the total tumor volume and sLDH was 0.59 (95%CI: 0.776–0.836). These results 
showed positive correlation of between the total tumor volume and sNSE or sLDH. 
We examined the secretion of NSE in the melanoma cell lines because there are no 
published in vitro data regarding this phenomenon. We used four melanoma cell lines 
with differing melanin production abilities, and the results of our analyses showed that 
the difference in melanin synthesis activity was not related to the NSE concentration in 
the cell lysates or the supernatants. NSE was detected in all four melanoma cell lines and 
one glioma cell line but not in cultured fibroblasts. The amounts of NSE in the 
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supernatants varied from 0.30 ng/ml to 237.31 ng/ml. Interestingly, the supernatants of 
two cultured cell lines with high NSE contained many dead cells compared to the other 
two cultured cell lines. Further investigation is required to clarify whether the necrosis or 
apoptosis of melanoma cells is important to increase the concentration of NSE. 
This study has several limitations: the small number of patients, the limited 
duration of the follow-up, and the retrospective study design. Therefore, we couldn’t 
assess the association between sNSE levels and melanoma-specific survival or distant 
metastatic-free survival. Another remaining question is whether sNSE is a useful marker 
for predicting clinical response to systemic therapy, similar to sLDH. 
In conclusion, the present study showed that there were 27% of cases showing 
elevated sNSE but normal sLDH in stage IV and 80% of them were mucosal melanoma. 
Despite the limited cases, the change of sNSE more closely corresponded to disease 
progression or clinical response to therapy than sLDH. Our findings indicate that the 
combination of sNSE and sLDH could contribute to a more accurate evaluation of disease 




Fig. 1. sNSE levels according to the stage. This showed sNSE levels in the patients with 
malignant melanoma at each stage. The sNSE levels in the stage IV patients were higher 
than those of the stage I/II and III patients. Dotted bar: The upper normal limit of NSE 
(15.2 ng/ml). 
 
Fig. 2. Immunohistochemistry of NSE A) #5 patient sample. The specimen didn’t 
express NSE. B) #12 patient (with normal sNSE level) sample showed focally 
expression. C) #17 patient (with elevated sNSE level) sample showed strong diffuse 
expression of NSE IHC. 
 
Fig. 3. Correlations between the tumor volume and sNSE or sLDH in the stage IV 
melanoma patients. Top row: The sNSE and tumor volume of each patient. Bottom row: 
The sLDH and tumor volume of each patient. 
 
Fig. 4. The sNSE and sLDH levels during the course of disease in each stage IV patient. 
▲ graph: The changes in sNSE. ■ graph: The changes in sLDH. Solid lines: The 
change in the total tumor volume. Dotted bars: The upper normal limit of sNSE and sLDH.  
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The movement of the patients' sNSE and sLDH values basically corresponded to the total 
tumor volume. Patient 4 and 10 showed different movements the sNSE and sLDH 
changes and the tumor volume changes. The patient numbers in this figure correspond to 
the patients in Table 1. 
 
Fig. 5. Results of the ENO2 ELISA (A) cell lysates, (B) supernatants, and (C) dead cell 
numbers in the supernatants by cell lines. 
 
Table 1. Characteristics of all stage patients in this study. 
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Table 1 Characteristics of all stage patients in this study
No Age/Sex Primary TT 
(mm)





1 64/ F mucosal - lymph node, peritoneal ＋ (P, M) WT
2 82/M acral - lymph node, brain, lung ＋(M) V600E
3 64/M mucosal - liver, lung NS WT
4 87/ F acral 1.5 in-transit, lung, skin, 
lymph node
＋ (P, M) WT
5 80/ F mucosal - skin, bone, liver － (P, M) WT
6 89/M acral 6.0 lymph node, liver, bone, 
spine
＋ (P) WT
7 40/ F acral 1.3 lymph node, brain NS WT
8 53/M mucosal - lymph node ＋ (M) WT
9 85/M acral 7.0 lymph node ＋ (P, M) WT
10 80/ F acral 8.0 liver, lung, lymph node ＋ (P, M) WT
11 67/ F cutaneous 5.0 in-transit, lymph node, 
liver, lung
＋(P, M) V600E
12 80/ F mucosal 6.0 Brain ＋ (P, M) WT
13 84/ F mucosal - liver, lymph node, 
urethra
NS WT
14 64/ F mucosal 6.0 brain, liver, lung ＋ (M) WT
15 88/ F acral 7.0 lung, liver, lymph node ＋ (P, M) WT
16 66/M mucosal - lymph node, liver ＋ (P) WT
17 64/M cutaneous - liver, lung, lymph node ＋ (M) V600E
18 83/ F cutaneous 5.0 lymph node, lung ＋ (P) WT




1 44/ M cutaneous 2.0 WT
2 80/ F acral - V600E
3 58/ M acral 5.5 NS
4 66/ F acral 1.7 NS
5 56/ F acral 2.1 NS
6 66/ F acral 2.5 WT
7 83/ F acral 3.0 NS
8 69/ M acral 6.0 NS
9 84/ M acral 0.45 NS
10 83/ F acral 5.0 WT
stage IV patients stage III patients




1 64/ M acral 0.55 WT
2 81/F acral 0.45 NS
3 53/F cutaneous 2.7 NS
4 58/ F acral 2.4 WT
5 71/ M acral 4.5 WT








Table 2 The relationships between the sNSE and sLDH levels in the stage IV group




















sLDH elevated sLDH normal
sNSE elevated 6 (33.3%) 5 (27.8%)





Figure 1 sNSE levels according to the stage
Stage I/ II Stage III Stage IV
Median 12.7 Median 12.1
Median 16.3
* *
* * ： p < 0.01
UNL of NSE









* * ： p < 0.05
Figure 2 Immunohistochemistry of NSE
A B
C
Figure 3 Correlations between the tumor volume and sNSE or sLDH





































































































































































































































































































c) dead cell count
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